Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Purdue Pharma
Biotech
Amyloidosis biotech Attralus nabs $116M for clinical development
Attralus Therapeutics has scored $116 million to bring a handful of amyloidosis therapies into the clinic.
Emmy Lucas
Sep 8, 2021 3:28pm
Purdue subsidiary buys non-opioid pain prospect
Aug 11, 2021 8:20am
Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus
May 11, 2021 11:05am
Former Merrimack CEO becomes new Yumanity chief—Chutes & Ladders
Jul 12, 2019 9:30am
Purdue hires Ducharme as CSO to aid expansion beyond opioids
Jul 3, 2019 10:35am
Eisai buys Purdue stake in insomnia drug as PDUFA date nears
May 1, 2019 9:28am
